News
Zacks.com on MSN21h
Will New CEO's Leadership Propel Novo Nordisk's Next Growth Wave?
Maziar Mike Doustdar takes office as NVO's new CEO, bringing a proven global growth record to tackle rising obesity market ...
Novo Nordisk has a commercial relationship with Economist Impact, a division of The Economist Group. The Economist operates ...
Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma ...
C’était l’histoire dont tout le monde parlait. En 2024, Novo Nordisk, grâce à ses traitements révolutionnaires contre l’obésité, s’imposait comme la première capitalisation boursière d’Europe, ...
The Q2 pharma earnings season featured changes in the obesity race as well as insights into drugmakers’ views on tariffs and drug pricing.
Novo Nordisks stock has tumbled from record highs after slashing its 2025 outlook, as fierce competition, leadership changes, ...
The Largest Healthcare Companies by Market Cap in August 2025 Eli Lilly, Johnson & Johnson, and AbbVie command the healthcare sector.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback